AUDICOR Technology has been shown to be able to detect hemodynamic changes associated with Heart Failure and assess the prognosis of patients' disease course upon hospital discharge. There are two obvious next evolutions for AUDICOR Technology: first, to be able to monitor cardiac status outside of the hospital, clinic or physician's office; and second, integration into all devices that monitor ECG to add hemodynamic parameters for better diagnoses.
Home monitoring capability has been initiated with the US and European clearance of the AUDICOR AM 48-hour ambulatory monitor. This trend can be extended through integration with wireless technology for automated transmission of the data from the home, incorporation of the sensor system within wearable devices, and ultimately merged with an implantable loop recorder for long term monitoring for diagnosis and assessment of therapy for a wide range of cardiac disorders.
These future applications of AUDICOR Technology can lead to management of not just Heart Failure but associated conditions and comorbidities such as silent ischemia and sleep apnea. Inovise is actively seeking additional strategic partners to extend the utilization of AUDICOR Technology through both distribution and development agreements.
The AUDICOR® Technology can be integrated into nearly any form of cardiac monitoring device from treadmills to transport monitors to automatic external defibrillators to implantable devices. As such, Inovise has attracted attention from some of the largest and most innovative medical companies in the industry and is actively pursuing strong strategic partners. Inovise has already entered into development agreements with companies such as Welch Allyn and Zoll and is in discussions with several other forward thinking enterprises in the Cardiac Rhythm Management arena and the field of cardiac diagnostics.
These current and future strategic partners share an understanding of the potential for Acoustic Cardiography to enhance the specificity of current ECG based systems for the evaluation of Heart Failure. They recognize the value of expanding the application of AUDICOR Technology to the areas of Sleep Apnea and Silent Ischemia, which are currently under development. Preliminary research demonstrates that this technology could be the optimal tool to listen for the "Sounds of Silence" that may lead to early detection and intervention for common comorbidities of heart failure and possible prevention of Acute Coronary Syndrome (ACS).